On the other hand, INSL-5 targets a GPCR known as GPR142, also known as RXFP4, a receptor found to be expressed by the NCI-H716 cell line (54), and both α and β-cells in the pancreas, and its activation directly stimulates the expression of GLP-1 and insulin, representing a possible new pharmacological tool for the treatment of type 2 diabetes (77, 221), and supporting a possible role for INSL-5 in the incretin effect. The gene discussed is GPBAR1; the disease is type 2 diabetes mellitus.